Deloitte Digital and Salesforce announced plans to accelerate CRM innovation for the BioPharma industry. As this sector rapidly evolves, legacy platforms struggle to keep pace, hampering progress and innovation. Informed by Deloitte Digital's deep life sciences and health care experience serving clients around the world and Salesforce's CRM technology, the two organizations intend to develop new solutions to advance BioPharma innovation.
The BioPharma industry is undergoing rapid transformation driven by data analytics, catalyzing the creation of specialty drugs and advanced and personalized therapies that require more patient and health care provider engagement. Many BioPharma organizations rely on outdated legacy platforms ill-equipped for this shift in treatments.
Brett Davis, Deloitte's chief innovation officer, highlights the urgency of modernization, "BioPharma is experiencing groundbreaking advancements in treatments and personalized medicine. However, existing platforms, from research and development to commercial engagement, no longer align with the industry's dynamic requirements. Our collaboration with Salesforce is a commitment to pioneer the next generation of innovations that help enable the rapid scientific and technological progress of this sector."
Deloitte and Salesforce's collaboration will empower BioPharma firms to bring innovative therapies to patients faster. In a competitive industry, speed to market is crucial. This collaboration intends to equip organizations with the tools needed to excel and impact patient outcomes positively.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!